Vincristine Production Cost Reports

The report provides a detailed analysis essential for establishing a Vincristine production plant. It encompasses all critical aspects necessary for Vincristine production, including the cost of Vincristine production, Vincristine plant cost, Vincristine production costs, and the overall Vincristine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Vincristine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Vincristine is an alkaloid chemotherapy agent which is derived from the Madagascar periwinkle plant. It works by binding to tubulin proteins in cancer cells to prevent microtubule assembly, essential for cell division during mitosis, which stops tumour growth in rapidly proliferating malignancies.

It is FDA-approved for pediatric and adult acute lymphoblastic leukaemia as part of multi-agent regimens like hyper-CVAD or VPLD, Hodgkin lymphoma, and non-Hodgkin lymphoma. It treats Ewing sarcoma, medulloblastoma/CNS embryonal tumours, small cell lung cancer, multiple myeloma (VAD with doxorubicin), ovarian carcinoma, and non-malignant thrombotic thrombocytopenic purpura (TTP) via immunosuppression.

The market for Vincristine is influenced by a rise in global cancer incidence, particularly leukaemia, lymphoma, neuroblastoma, and pediatric malignancies. The growth in ageing populations, enhanced diagnostics, and expanded use in combination regimens like CHOP or hyper-CVAD contribute to its market demand. Also, advancements in liposomal and oral formulations, improved supportive therapies for neuropathy and constipation, and policy support for oncology access in emerging markets fuel its demand.

The industrial Vincristine procurement is affected by recurrent shortages because of limited manufacturers, reliance on a few API suppliers with complex natural extraction from periwinkle, and production vulnerabilities in sterile injectables. Other factors like generic competition impact pricing, while regulatory compliance (DMF and CEP), cold-chain logistics, and geopolitical API risks influence its sourcing.

Raw Material for Vincristine Production

According to the Vincristine production plant project report, the key raw materials used in the production of Vincristine include periwinkle Plant Material, Benzene, Acetic Acid, and Aluminium Oxide.

Production Process of Vincristine

The extensive Vincristine production cost report consists of the following major industrial production process:

1. From Periwinkle Plant: The production of  Vincristine uses the periwinkle plant (Catharanthus roseus), which has the natural alkaloids inside its leaves and stems. The plant is ground and soaked in benzene solvent to pull out all the alkaloids. This forms a thick mixture called alkaloid tartrate. This is purified by running it through a special column packed with aluminium oxide that has been treated and deactivated with acetic acid to separate Vincristine from other similar alkaloids like vinblastine. The pure vincristine fraction is dried and turned into the final drug form for medical use.

Vincristine is a vinca alkaloid antineoplastic agent with the molecular formula C46H56N4O10 and a molecular weight of 824.97 g/mol. It appears as a white to off-white crystalline solid or needle-like crystals (when recrystallised from methanol). It has a melting point of 211–220  degree Celsius, low aqueous solubility (about 2.27 mg/L at neutral pH), and specific optical rotation values (in ethylene chloride). It has a complex polycyclic structure with indole, piperidine, and quinoline ring systems, including a formyl group at one nitrogen, three hydrogen bond donors, nine acceptors, and a polar surface area of 171.17 Ų. It has a logP value of 2.82 and 10 rotatable bonds. It is heat-sensitive, incompatible with strong oxidants.